| Patent application number | Description | Published |
|---|
| 20080226695 | THIN FILM WITH NON-SELF-AGGREGATING UNIFORM HETEROGENEITY AND DRUG DELIVERY SYSTEMS MADE THEREFROM - The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. | 09-18-2008 |
| 20080260805 | THIN FILM WITH NON-SELF-AGGREGATING UNIFORM HETEROGENEITY AND DRUG DELIVERY SYSTEMS MADE THEREFROM - The invention relates to film products containing desired levels of active components and methods of their preparation. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. Desirably, the films may be exposed to temperatures above that at which the active components typically degrade without concern for loss of the desired activity. | 10-23-2008 |
| 20080260809 | POLYETHYLENE OXIDE-BASED FILMS AND DRUG DELIVERY SYSTEMS MADE THEREFROM - The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. The films contain a polymer component, which includes polyethylene oxide optionally blended with hydrophilic cellulosic polymers. Desirably, the films also contain a pharmaceutical and/or cosmetic active agent with no more than a 10% variance of the active agent pharmaceutical and/or cosmetic active agent per unit area of the film. | 10-23-2008 |
| 20080268027 | THIN FILM WITH NON-SELF-AGGREGATING UNIFORM HETEROGENEITY AND DRUG DELIVERY SYSTEMS MADE THEREFROM - The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. | 10-30-2008 |
| 20090058061 | SYSTEM FOR PROVIDING AN INDICATION INDICATIVE OF WHETHER OR NOT A SEAT BELT OF A VEHICLE OCCUPANT IS FASTENED - A system for providing an indication indicative of whether or not a seat belt of a vehicle occupant is fastened includes a seat belt system including a seat belt and a visible marking provided on the seat belt, the marking being visible from outside the vehicle when the seat belt is fastened. Alternatively, the system includes a seat restraint system including a seat restraint system for a passenger including a seat restraint having a locked position for restraining the passenger in a seat, a sensor for sensing whether or not the seat restraint system is in the locked position, and an indicator responsive to the sensor, the indicator being accessible from outside the vehicle or at a location remote from the passenger, for displaying an indication indicative of whether or not the seat restraint system is in the locked position. | 03-05-2009 |
| 20100092545 | POLYETHYLENE-OXIDE BASED FILMS AND DRUG DELIVERY SYSTEMS MADE THEREFROM - The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. The films contain a polymer component, which includes polyethylene oxide optionally blended with hydrophilic cellulosic polymers. Desirably, the films also contain a pharmaceutical and/or cosmetic active agent with no more than a 10% variance of the active agent pharmaceutical and/or cosmetic active agent per unit area of the film. | 04-15-2010 |
| 20100317682 | Single Dosage Unit Including Opioid and Methylnaltrexone or Methylnaltrexone Salt - The use of methylnaltrexone bromide in combination and in one dosage unit, with any opioid drug in order to prevent the constipation which can be associated with opioids. | 12-16-2010 |
